Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 5, 2012, Pages 618-625

  Khandelwal, Nikhil ^a   Duncan, Ian ^a   Ahmed, Tamim ^b   Rubinstein, Elan ^b   Pegus, Cheryl ^a  

^a Walgreen   (United States)

^b Solucia Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; SORAFENIB; SUNITINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY CYCLE MANAGEMENT PROGRAM; CONTROLLED STUDY; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; EMERGENCY CARE; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN; PRESCRIPTION; SURVIVAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84861837707     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0063     Document Type: Article

References (18)

1. Schwartz RN, Eng KJ, Frieze DA, et al. NCCN Task Force report: specialty pharmacy. J Natl Compr Canc Netw 2010;8(Supp 4):S1-12.
2. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Supp 3):S1-14.
3. Vanelli M, Pedan A, Liu N, et al. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication non persistence in seven chronic illnesses. Clin Ther 2009;31:2628-2652.
4. Nexavar (sutent) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2010.
5. Sutent (sunitinib) [package insert]. New York, NY: Pfizer Inc.; 2010.
6. Cancer Therapy Evaluation Program. CTEP, NCI Guidelines: Adverse Event Reporting Requirements. Effective January 1, 2005. National Cancer Institute Web site. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/newadverse-2006.pdf. Accessed March 13, 2012.
7. Tarceva (erlotinib) [package insert]. Farmingdale, NY: OSI Pharmaceuticals, LLC; 2010.
8. Berger BA, Krueger KP, Felkey BG. The pharmacist's role in treatment adherence. Part 1: extent of the problem. US Pharmacist 2004;29:50-54.
9. Wolf MS, Davis TC, Shrank W, et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 2007;67:293-300. (Pubitemid 46990725)
10. Egorin MJ. Promises and pitfalls of oral cancer chemotherapy. Clin Adv Hematol Oncol 2009;7:S8-10.
11. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-1768.
12. Blansett L. Changing reimbursement policies and trends, presentation to association of community cancer centers. 2009. Available at: www.amcp.org/WorkArea/DownloadAsset.aspx?id=11843. Accessed March 20, 2012.
13. Outlook: state of the industry report 2009. Walgreens Specialty Pharmacy. Available at: http://www.walgreenshealth.com/pdf/newsletterreport/ SOIReport2009.pdf. Accessed March 13, 2012.
14. Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual. Version 2.0. June 1, 1999. National Cancer Institute Web site. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcmanual-v4-10-4-99.pdf. Assessed May 20, 2011.
15. Eisen T, Oudard S, Gravis G et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100:1454-1463.
16. Motzer RJ, Agarwal N, Beard C, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2, 2012. Available at: NCCN.org. Accessed March 24, 2011.
17. Moody M, Jackowski J. Are patients on oral chemotherapy in your practice setting safe? Clin J Oncol Nurs 2010;14:339-346.
18. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117. (Pubitemid 44288785)